According to Zacks, “J&J’s Pharma segment is performing well. We believe J&J’s diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. J&J has a deep and promising pipeline with a good new product launch record. However, challenges for the company remain in the form of generic competition, pricing pressure and pipeline setbacks. Quite a few products in the company’s portfolio including Invega and Ortho Tri-Cyclen Lo are facing generic competition. Moreover, biosimilar competition for Remicade entered several major EU markets in Feb 2015 while HCV sales continue to decline in the face of intense competition. Zytiga and Xarelto are also facing patent challenges in the U.S.”
Several other equities research analysts also recently issued reports on JNJ. BTIG Research restated a neutral rating on shares of Johnson & Johnson in a research report on Friday, June 3rd. Vetr downgraded shares of Johnson & Johnson from a hold rating to a sell rating and set a $109.97 price objective for the company. in a research report on Monday, June 6th. Wells Fargo & Co. restated a buy rating on shares of Johnson & Johnson in a research report on Monday, June 6th. Goldman Sachs Group Inc. set a $121.00 price objective on shares of Johnson & Johnson and gave the stock a neutral rating in a research report on Monday, June 13th. Finally, Jefferies Group reaffirmed a hold rating and set a $109.00 target price (up from $108.00) on shares of Johnson & Johnson in a report on Tuesday, June 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has an average rating of Hold and a consensus target price of $120.19.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.77% on Wednesday, hitting $118.47. The stock had a trading volume of 691,224 shares. The company has a 50 day moving average of $119.56 and a 200-day moving average of $116.58. Johnson & Johnson has a 12-month low of $91.76 and a 12-month high of $126.07. The firm has a market capitalization of $324.12 billion, a P/E ratio of 22.08 and a beta of 0.61.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Equities analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 2.68%. The ex-dividend date of this dividend was Friday, August 19th. Johnson & Johnson’s payout ratio is presently 60.15%.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
A number of large investors have recently modified their holdings of JNJ. Bank of Montreal Can purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $858,505,000. Emerald Acquisition Ltd. bought a new position in Johnson & Johnson during the second quarter worth $805,455,000. Vanguard Group Inc. boosted its position in Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the last quarter. BlackRock Fund Advisors boosted its position in Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the last quarter. Finally, Capital World Investors boosted its position in Johnson & Johnson by 10.3% in the second quarter. Capital World Investors now owns 22,025,323 shares of the company’s stock worth $2,671,672,000 after buying an additional 2,050,323 shares during the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.